Loading
journalsJournal
Journal of the National Comprehensive Cancer Network
JNCCN is the NCCN's journal, where the US treatment guidelines are published in article form alongside real-world practice and cost studies.
Also called: JNCCNJ Natl Compr Canc Netw
Overview
JNCCN appears monthly and publishes NCCN Guidelines Insights explaining panel changes, guideline-concordance and real-world outcome studies, and health-policy and economics research from US cancer centres. The bridge between the NCCN algorithms that drive US reimbursement and the evidence behind them.
Publisher
Harborside · National Comprehensive Cancer Network
Scope
oncology practice and policy
Website
Founded
2003
ISSN
1540-1405
guideline2026changed practice0 citations
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
NCCN is the source of the category grades on the triple-negative breast cancer page and the first major guideline to place an antibody-drug conjugate first line for the disease.
guideline2025changed practice64 citations
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
NCCN is the source of the category grades quoted on the gallbladder cancer page; the adjuvant section leans on BILCAP for capecitabine and on SWOG S0809 for chemoradiation after margin-positive or node-positive resection.
guideline2021changed practice983 citations
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
NCCN is the source of the category grades on the pancreatic cancer page and the guideline that first placed germline testing for every patient and universal tumour profiling in routine care.
real world201786 citations
Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma
ALK is the reason young, KRAS wild-type patients should have fusion testing even though the overall rate is one in six hundred.
Anne C. Chiang
SWOG Executive Officer, Breast and Lung; Associate Professor, Yale School of Medicine
Lung cancerSmall-cell lung cancerCooperative group trials
Anne Chiang is a thoracic oncologist overseeing SWOG's breast and lung trial portfolios.
Emily K. Bergsland
Professor of Medicine; Associate Director for Education, UCSF Helen Diller Family Comprehensive Cancer Center
Neuroendocrine tumoursGastrointestinal oncologyClinical trials
Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.
Ronan J. Kelly
Director, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas
Oesophageal cancerGastric cancerAdjuvant immunotherapy
Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease.
guidelineJournal of the National Comprehensive Cancer Network 2026changed practice0 citations
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
NCCN is the source of the category grades on the triple-negative breast cancer page and the first major guideline to place an antibody-drug conjugate first line for the disease.
guidelineJournal of the National Comprehensive Cancer Network 2025changed practice64 citations
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
NCCN is the source of the category grades quoted on the gallbladder cancer page; the adjuvant section leans on BILCAP for capecitabine and on SWOG S0809 for chemoradiation after margin-positive or node-positive resection.
guidelineJournal of the National Comprehensive Cancer Network 2021changed practice983 citations
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
NCCN is the source of the category grades on the pancreatic cancer page and the guideline that first placed germline testing for every patient and universal tumour profiling in routine care.